Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 500 | uM | 10077.049 | 0.9015 | 0.6528 | 0.5440 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 0.00064 | uM | 10265.021 | 1.0975 | 1.7012 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 0.0032 | uM | 10265.021 | 0.8280 | 0.0871 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 0.016 | uM | 10265.021 | 1.0968 | 1.6957 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 0.08 | uM | 10265.021 | 0.8751 | 0.2997 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 0.4 | uM | 10265.021 | 1.0599 | 1.4132 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 2 | uM | 10265.021 | 0.9611 | 0.7593 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 10 | uM | 10265.021 | 1.0755 | 1.5303 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 50 | uM | 10265.021 | 1.1381 | 2.0379 | 0.3095 | |
| MDA-MB-134-VI | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 250 | uM | 10265.021 | 0.5084 | -0.7752 | 0.3095 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.00064 | uM | 7879.017 | 1.0543 | 1.0604 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.0032 | uM | 7879.017 | 1.0311 | 1.0348 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.016 | uM | 7879.017 | 1.0679 | 1.0754 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.08 | uM | 7879.017 | 0.9711 | 0.9672 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.4 | uM | 7879.017 | 0.9262 | 0.9154 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 2 | uM | 7879.017 | 0.8500 | 0.8250 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 10 | uM | 7879.017 | 0.8466 | 0.8209 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 50 | uM | 7879.017 | 0.1983 | -0.1960 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 250 | uM | 7879.017 | 0.0053 | -0.8954 | 1.7754 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.00064 | uM | 10093.021 | 0.8477 | 0.6702 | 0.9172 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.0032 | uM | 10093.021 | 1.0261 | 1.0569 | 0.9172 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.016 | uM | 10093.021 | 0.7376 | 0.4351 | 0.9172 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.08 | uM | 10093.021 | 0.8385 | 0.6505 | 0.9172 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.4 | uM | 10093.021 | 0.6827 | 0.3192 | 0.9172 | |
| MDA-MB-157 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 2 | uM | 10093.021 | 0.8523 | 0.6802 | 0.9172 |